Welcome to my team page for the Alzheimer’s Association Walk to End Alzheimer's®! Walk is the largest event to raise funds and awareness for the care, support and research efforts of the Alzheimer’s Association®. It’s held annually in more than 600 communities nationwide, and our team is excited to participate this year. 

  Alzheimers is called the slow death because you loose a little bit of the person you love so dearly every single day. I know because I watched it happen to my father in law Edo. It was the longest goodbye having to watch a father/ grandfather who was once so capable, so intelligent, so full of life, who loved his wife, his children and grandchildren become totally dependent on others for daily care all the while not even recognizing his beloved family. Those years that we watched his slow decline were excruciating. Sometimes the only saving grace I had through it all was thinking that because of his incognizance, he was not as aware of his predicament as we his family were. He would have never wanted to live as he did his last few years. I think the most cruel part of this disease is the family left to watch this heart wrenching decline. And in the end all you have left are the memories of who your loved one once was. It is beyond heartbreaking.

  Not only is watching a parent slip away from this cruel disease hard but watching a spouse slip away due to Alzheimer's is heart-wrenching. I KNOW because I am living it. My husband Peter was diagnosed with early onset Alzheimer in 2023. An Alzheimers diagnosis involves witnessing the gradual loss of shared memories and the transformation of the person you love. Coping requires a delicate balance of acceptance, resilience, and seeking support from others who understand the challenges. Embracing the remaining moments of connection and finding ways to communicate beyond words become crucial. 

Because of your support there are more promising treatments on the horizon. Peter has begun an anti-amyloid antibody intravenous (IV) infusion therapy that will be delivered every 4 weeks.  Donanemab (Kisunla) has received traditional approval from the FDA to treat early Alzheimers disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimers disease who have confirmation of elevated beta-amyloid in the brain.

The positive data from the clinical studies showed that Donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimers Disease. 

  I need your help to end this devastating disease  You can make an impact with a donation or even consider joining my TEAM. Your kindness and generosity truly make a difference in the fight against Alzheimer’s and other dementia. Thank you for your support. Lynn